J Biol Chem, Vol. 274, Issue 36, 25743-25748, September 3, 1999
Evidence for a p21ras/Raf-1/MEK-1/ERK-2-independent
Pathway in Stimulation of IL-2 Gene Transcription in Human Primary
T Lymphocytes*
Virginie
Lafont
§,
Florence
Ottones¶,
Janny
Liautard¶, and
Jean
Favero¶
From the
Lymphocyte Activation Laboratory, Imperial
Cancer Research Fund, London, United Kingdom WC2A 3PX and
¶ INSERM U431, Microbiologie et Pathologie Cellulaire Infectieuse,
Université de Montpellier II, Place Eugène Bataillon, cc
100, 34095 Montpellier cedex 05, France
 |
ABSTRACT |
T cell stimulation leads to triggering of signals
transmitted from the cell membrane to the nucleus through TCR/CD3
proteins. Characterization of these signals largely results from the
use of cell lines stimulated with anti-CD3 monoclonal antibodies. These
studies have established that activation caused a rapid increase in the
formation of GTP-bound Ras, which stimulates the mitogen-activated
protein kinase pathway involving the extracellular-regulated kinase-2
(ERK-2) and activates the nuclear factor of activated T cells (NF-AT)
that regulates interleukin-2 (IL-2) gene transcription. In the present
study, we used human primary T cells, and we investigated the
intracellular signals triggered by two different anti-CD3 monoclonal
antibodies (UCHT1 and X-35), which both strongly induce cell
proliferation. We found that, in contrast to the commonly used UCHT1,
X-35 activated IL-2 gene transcription without stimulation of the
Raf-1/mitogen-activated ERK kinase-1 (MEK-1)/ERK-2 phosphorylation cascade; we also showed that X-35 stimulation, which triggers an
ERK-2-independent pathway, does not involve activation of
p21ras. In addition to demonstrating that activation of
p21ras and of its Raf-1/MEK-1/ERK-2 effector pathway is not an
event obligatorily triggered upon TCR/CD3 ligation, these results
provide the first evidence of the existence of a
p21ras/ERK-2-independent pathway for IL-2 gene transcription in
human primary T lymphocytes.
 |
INTRODUCTION |
Binding of monoclonal antibodies to the CD3 complex has been used
as model system that mimics antigen recognition to characterize the
biochemical events leading to interleukin-2 production and T cell
proliferation. Several studies have brought evidence that the
intracellular signals that mediate activation of transcription factors
regulating IL-21 gene
transcription in human T cells involve p21ras-mediated
signaling pathways (1-5). These studies obtained with T cell lines
collectively suggest that the Raf-1/MEK-1/ERK-2 phosphorylation cascade
is the necessary (6-8) (if not sufficient (9)) p21ras effector
pathway for nuclear factor of activated T cell (NF-AT) induction in
human T cells. These conclusions, which mainly result from the
expression of dominant negative or constitutively active p21ras
(4-6), Raf-1 (10), or MEK-1 (4, 9, 11) mutants in Jurkat cells, have
created a paradigm that p21ras/ERK-2 pathway is the major route
for activation of IL-2 gene transcription in TCR/CD3 induced activation
of T lymphocytes. However, it cannot be excluded that an
ERK-2-independent pathway might be used in primary T cells. Indeed a
result obtained with splenocytes from transgenic mice expressing an
inactive form of MEK-1 (12) suggested the possibility of the existence
of a TCR/CD3-induced MEK-1/ERK-2-independent pathway even though one
can question whether these cells, which developed in the absence of
positive selection, are representative of a normal T lymphocyte
population. Therefore, a clear physiological involvement of the MEK/ERK
cascade in T cell activation is still a matter of debate, in part due
to the fact that molecular genetic approaches are limited to cell lines or transgenic animals. Our aim was to study whether the stimulatory signals from the TCR/CD3 complex that promote IL-2 gene transcription obligatorily involve the p21ras/Raf-1/MEK-1/ERK-2 pathway in
primary T cells. We used highly purified CD4+ human
lymphocytes that we stimulated with UCHT1 or X-35, two mitogenic
anti-CD3 mAb (13, 14) recognizing the
chain of the CD3 complex (15)
but presenting a pan thymocyte reactivity and a specific medullary
thymocyte reactivity, respectively (14). We analyzed the effect of
these antibodies on the Raf-1/MEK-1/ERK-2 phosphorylation cascade. We
found that, in contrast to what happens with UCHT1, activation of IL-2
gene transcription triggered upon X-35 ligation occurred without
activation of the Raf-1/MEK-1/ERK-2 pathway; moreover, we showed that
this ERK-2-independent pathway does not involve activation of
p21ras. Altogether, the results we present herein demonstrate
that activation of p21ras/Raf-1/MEK-1/ERK-2 phosphorylation
cascade is not an obligatory event triggered upon TCR/CD3 ligation;
moreover, they bring evidence that activation of this cascade is not
essential for IL-2 gene transcription in human T lymphocytes.
 |
MATERIALS AND METHODS |
Chemicals and Reagents
UCHT1 (IgG1) and X-35 (IgG2a) anti-CD3 mAb were from Immunotech
(Marseille, France), mouse anti-phosphotyrosine mAb (4G10) was from
Upstate Biotechnology Inc. (Lake Placid, New York); rabbit anti-ERK-2
Ab, rabbit anti-Raf-1 Ab, and rabbit anti-ZAP-70 Ab were from Santa
Cruz Biotechnology (Santa Cruz, CA). Horseradish peroxidase-conjugated
rabbit anti-mouse and donkey anti-rabbit were from Amersham Pharmacia
Biotech. Rabbit anti-phosphoserine 473 PKB and PD098059 were from New
England Biolabs Inc. (Beverly, MA), and PMA and myelin basic protein
(MBP) were from Sigma. GST-Elk-1 was obtained from Dr. A. Nordheim
(Tubingen University, Germany).
Cell Preparation and Culture
Peripheral blood monocyte cells were isolated from peripheral
blood from healthy donors. Monocytes were removed by plastic adherence,
and CD4+ T cells were purified (>99% pure) by positive
immunoselection using magnetic beads coated with anti-CD4 mAb (Dynal
International, Oslo, Norway) according to the manufacturer's
instructions. Before being used, CD4+-purified T cells were
left 15 to 18 h in RPMI 1640 supplemented with 10% fetal calf
serum and gentamycin at 37 °C in a 5% CO2-humidified atmosphere. CD4+ cells were stimulated (72 h) either with
soluble anti-CD3 mAb or with anti-CD3 coated on anti-IgG-conjugated
beads. Proliferation was estimated by a 4-h [3H]thymidine incorporation.
Analysis of IL-2 mRNA Expression by Reverse
Transcription-Polymerase Chain Reaction
CD4+ T cells were stimulated for 6 h in the
presence of 1 µM ionomycin and anti-CD3 mAb (1 µg/ml).
The cells were treated with PD098059 (30 µM) as
described. Total RNA isolation, reverse transcription reaction, and
polymerase chain reaction were performed as already described (16).
Analysis of MAP Kinase Activation
Analysis of MAP Kinase Phosphorylation--
This analysis was
performed as described (16). Briefly, CD4+ cells (5 × 106/ml) were stimulated with anti-CD3 mAb (10 µg/ml) or
phorbol esters (PMA or phorbol dibutyrate (PDBu)). The supernatants
were resolved in a 12.5% SDS-PAGE, and the gel was transferred onto a
PVDF membrane (polyscreen, NEN Life Science Products). After blocking
of nonspecific binding, the membrane was probed with anti-ERK-2 Ab (0.2 µg/ml) and revealed with horseradish peroxidase-conjugated
anti-rabbit antibody (1:20,000) followed by enhanced chemiluminescence
detection system (NEN Life Science Products). Reprobing of the same
blots with the anti-phosphotyrosine mAb 4G10 (1 µg/ml) was performed after stripping of bound Ab. The membrane was revealed with 1:10,000 solution of horseradish peroxidase-conjugated-anti-mouse Ab and the
chemiluminescence detection system. Raf-1 was similarly revealed on
PVDF membranes electroblotted from 8% SDS-PAGE (anti-Raf-1 antibody
was used as 0.5 µg/ml).
Analysis of MAP Kinase Activity Using MBP as Substrate--
This
experiment was done as described (16). Stimulated cells were lysed, and
ERK-2 was immunoprecipitated with 1 µg of anti-ERK antibody and
protein A-Sepharose. After washing, in vitro phosphorylation was carried out for 20 min at 30 °C in kinase buffer with 10 µg of
MBP, 50 µM ATP, 1 µCi of [
-32P]ATP.
Proteins were resolved in 10% SDS-PAGE, electroblotted and visualized
by autoradiography, and quantitatively analyzed with a PhosphorImager
(Molecular Dynamics, Inc.).
Analysis of MAP Kinase Activity Using GST-Elk-1 as
Substrate--
GST-Elk-1 phosphorylation was performed as already
reported (17). Briefly, activated cells were lysed, and the
supernatants were mixed with GST fusion protein kinase substrate and
glutathione-agarose (Sigma) and incubated overnight at 4 °C. The
substrate-agarose complexes were washed, and in vitro
phosphorylation was carried out for 20 min at 30 °C in kinase assay
buffer. Proteins were fractionated by 10% SDS-PAGE,
electrotransferred, and revealed by autoradiography.
Analysis of p21ras Activation
Purified CD4+ cells (20.106/ml) were
incubated with anti-CD3 mAb (10 µg/ml) or phorbol esters (PDBu, 50 ng/ml) and then lysed for 30 min in cold lysis buffer (50 mM Hepes, pH 7.4, 10 mM NaF, 10 mM
iodoacetamide, 75 mM NaCl, 1% Nonidet P-40, 10 mM MgCl2, 1 mM phenylmethylsulfonyl
fluoride, 1 mM Na2VO3, and
pepstatin A, chymostatin, and leupeptin (each at 1 mg/ml). The
supernatant were mixed with GST-Ras binding domain of Raf (RDB) fusion
protein (10 µg/ml) (a generous gift from Dr. Julian Downward,
Imperial Cancer Research Fund, London) and glutathione-agarose (Sigma) for 2 h at 4 C. GST-RBD contains the Ras binding domain of Raf and
binds only the active form of Ras (19). Protein-agarose complexes were
washed and solubilized in electrophoresis buffer. Proteins were
resolved in 15% SDS-PAGE and electroblotted. The membrane was revealed
with an anti-Ras mAb (Calbiochem).
Analysis of p56lck Autophosphorylation
These experiments were done as in Lafont et al. (18).
Briefly, 107 CD4+ T cells stimulated with PDBu
or with anti-CD3 mAb were lysed, and p56lck was
immunoprecipitated with rabbit anti-p56lck polyclonal Ab (a
generous gift from Dr. S. Fisher, Hôpital Cochin, Paris, France)
and protein A-Sepharose. Complexes were resuspended in kinase buffer,
and autophosphorylation of p56lck was determined in the
presence of 5 µCi of [
-32P]ATP (6000 Ci/mmol, NEN
Life Science Products). Radiolabeled protein were then resolved on 8%
SDS-PAGE, blotted onto PVDF membrane. and detected by autoradiography.
Analysis of ZAP-70 Tyrosine Phosphorylation
5 ×107 unstimulated CD4+ T cells as
well as X-35-or UCHT1-stimulated cells (5 min at 37 °C) were lysed
in lysis buffer, and ZAP-70 was immunoprecipitated with rabbit
anti-ZAP-70 polyclonal antibody and protein A-Sepharose.
Immunoprecipitate complexes were recovered and solubilized in
electrophoresis buffer. After SDS-PAGE and electroblotting, the
membrane was revealed with antiphosphotyrosine 4G10. The blot was then
reprobed after stripping of bound Ab with anti-ZAP-70 antibody.
Analysis of PKB/Akt Phosphorylation
Purified CD4+ cells (5.106/ml) were
incubated with anti-CD3 mAb (10 µg/ml) for the indicated times and
lysed in a lysis buffer comprised of 50 mM Hepes, pH 7.9, 1% Nonidet P-40, 150 mM NaCl, 0.1 mM EDTA, 10 mM NaF, 1 mM Na3VO3, 1 mM phenylmethylsulfonyl fluoride, 1 mM
iodoacetamide, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml
chymostatin. The supernatants were resolved in a 7.5% SDS-PAGE, and
the gel was transferred onto a PVDF membrane. After blocking of
nonspecific binding, the membrane was probed with a rabbit
antiphosphoserine 473 PKB Ab (1:1000) and revealed with horseradish
peroxidase-conjugated anti-rabbit antibody (1:2000) followed by
enhanced chemiluminescence detection. Reprobing of the same blots with
the anti-PKB Ab (1:1000) was performed after stripping of bound Ab. The
membrane was revealed with 1:2000 solution of horseradish
peroxidase-conjugated-anti-rabbit Ab and the chemiluminescence detection system. Raf-1 was similarly revealed on PVDF membranes electroblotted from 8% SDS-PAGE (anti-Raf-1 antibody was used as 0.5 µg/ml).
Analysis of Tyrosine Phosphorylation
Cells were stimulated and lysed as described for MAP kinase
phosphorylation studies. The proteins were resolved on 10% SDS-PAGE, and the gel was transferred onto a PVDF membrane. After blocking of
nonspecific binding, the membrane was probed with the
anti-phosphotyrosine 4G10 antibody (1 µg/ml) and revealed with a
1:10,000 solution of horseradish peroxidase-conjugated anti-mouse Ab
followed by enhanced chemiluminescence detection system.
 |
RESULTS |
Analysis of MAP Kinase Pathway Activation in CD3-stimulated
Cells--
We first showed that highly purified CD4+ T
cells that do not respond to soluble anti-CD3 mAb are activated by and
proliferate in response to both X-35 and UCHT1 when coated on beads
(Table I).
View this table:
[in this window]
[in a new window]
|
Table I
Proliferative response of T cells to X-35 and UCHT1 stimulation
CD4+-purified T lymphocytes from healthy donors were stimulated
(for 72 h) with optimal doses of soluble X-35 or UCHT1 or with the
anti-CD3 mAb previously coated on anti-mouse IgG-conjugated magnetic
beads. Proliferation was estimated by [3H]thymidine
incorporation (cpm ± S.D.). S.D. was calculated from quadruplicates.
This experiment is representative of three. NS,
nonstimulated.
|
|
We then analyzed phosphorylation (appearance on electroblot of a slow
migrating band) (20, 21) and activation of ERK-2. Fig.
1A shows that a shifted band,
not present after 1-min stimulation, is clearly detected by anti-ERK-2
Ab after a 5-min activation with UCHT1, then diminishes after 15 min
and is no more detectable after 20 min. Conversely, no shifted band can
be detected in X-35 stimulation at any time of the analysis. These
experiments were performed using 10 µg/ml anti-CD3 mAb. We checked
that the difference between the two mAb in term of ERK-2 activation is
also observed in a large concentration range (1 to 20 µg/ml) (data
not shown).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
Study of the activation of ERK-2 upon X-35
and UCHT1 stimulation in CD4+-purified T cells.
CD4+-purified T cells were stimulated with X-35 or with
UCHT1 for 1 or 20 min (a 5-min PMA stimulation was used as control).
A, ERK-2 corresponding bands were detected on blotted
membranes using anti-ERK-2 antibody. The result shows the presence of a
shifted form in PMA and UCHT1 activation and not of X-35 stimulation.
B, parallel detection of ERK-2 with anti-ERK-2 Ab and
tyrosine phosphorylation of ERK-2 with anti-phosphotyrosine Ab after a
5-min stimulation confirm that phosphorylation of ERK-2 occurs in PMA-
and UCHT1- but not in X-35-activated cells. C, kinase
activity of immunoprecipitated ERK-2 protein was estimated using MBP as
an exogenous substrate. The percent intensity estimated on the
PhosphorImager was as follow: nonstimulated (NS) 100%, PMA
272%, X-35 (5) 104%, UCHT1 (5) 161%, X-35 (15) 106%, UCHT1 (15)
100%. D, kinase activity of ERK-2 from stimulated cell
lysates was estimated using GST-Elk-1 as substrate. The two latter
results demonstrate that ERK-2 enzyme activity can only be detected in
PMA- and UCHT1-stimulated cells and not in X-35-treated lymphocytes.
Each experiment is representative of three.
|
|
A parallel study analyzing tyrosine phosphorylation after a 5-min
stimulation similarly showed (Fig. 1B) that ERK-2 was
tyrosine-phosphorylated in UCHT1 but not in X-35-stimulated cells. We
also established that only ERK-2 immunoprecipitated from UCHT1 (or
PMA)-treated cells was able to phosphorylate (maximum after a 5-min
stimulation) over basal level MBP when used as exogenous substrate
(Fig. 1C). Enzymatic activity was confirmed using GST-Elk-1,
the GST fusion protein of ERK-2 physiological substrate (22), which was
highly phosphorylated by lysates from cells pretreated with PMA or
UCHT1 but not from cells treated with X-35 (Fig. 1D). It is
noteworthy that we did not detect phosphorylation of ERK1 in neither
X-35- nor UCHT1-stimulated cells (not shown).
Analysis of Raf-1, the upstream kinase in the MAP kinase cascade, shows
that this MAP kinase kinase kinase is also phosphorylated upon UCHT1
and PMA stimulation but not upon X-35 activation (Fig. 2).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 2.
Study of the activation of Raf-1.
CD4+-purified T cells were stimulated with X-35 or with
UCHT1 for 5 and 15 min (PMA stimulation was used as control). Raf-1 was
detected using anti-Raf-1 antibody; the result shows the presence of a
shifted form of Raf-1 upon UCHT1 stimulation and not upon X-35
treatment. Each experiment is representative of at least three.
NS, nonstimulated.
|
|
Analysis of Interleukin-2 mRNA Expression in CD3-stimulated
Cells--
IL-2 gene transcription, a key event in T cell activation
and proliferation, is regulated by the coordinate action of multiple nuclear factors including NF-AT. Previous results have brought evidence
that NF-AT activation is directly dependent on stimulation of
Raf-1/MEK-1/ERK-2 phosphorylation cascade. Since our preceding results
suggested that this pathway is not activated in X-35 stimulation, we
questioned whether IL-2 gene transcription could occur when the ERK-2
pathway is blocked with PD098059, a specific inhibitor of MEK-1 (23).
Fig. 3A confirms that ERK-2
activation, which only occurs in UCHT1 and PMA stimulation (as assessed
by the appearance of a slower migrating band and the phosphorylation of
GST-Elk-1), is indeed prevented by PD098059. In parallel, Fig.
3B shows that, in the absence of inhibitor, IL-2 mRNA
expression is induced by both mAbs, whereas in the presence of
inhibitor, IL-2 mRNA expression is blocked in UCHT1-stimulated
cells and is not in X-35-activated cells. This result demonstrates that
IL-2 gene transcription triggered upon X-35 ligation does not involve
activation of Raf-1/MEK-1/ERK-2 pathway.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 3.
Parallel analysis of IL-2 mRNA expression
and ERK-2 activation. Effect of PD098059. A, activation
of ERK-2 from X-35- or UCHT1-stimulated T cells was evaluated according
to its phosphorylation state (using anti-ERK-2 Ab) and kinase activity
(using GST-Elk-1 as substrate). PMA stimulation was used as the
control. This experiment was performed in the absence or presence of
PD098059. This representative set of experiments was performed twice.
B, IL-2 mRNA from purified CD4+ cells
stimulated with X-35 or UCHT1 in the presence of ionomycin was detected
by reverse transcription-polymerase chain reaction. These experiments,
performed in the absence or in the presence of PD098059, a specific
inhibitor of MEK-1 which blocks activation of ERK-2, show that
inhibition of ERK-2 has no effect on IL-2 mRNA expression induced
upon X-35 stimulation. 2-Microglobulin mRNA
expression is used as an internal standard. This is a representative
experiment of three. NS, nonstimulated.
|
|
Effect of X-35 and UCHT1 Treatment on p21ras
Activation--
Raf-1/MEK-1/ERK-2 has been described as a
p21ras effector pathway for NF-AT induction in Jurkat T cells.
Rac-1, along with other possible pathways, has also been shown in
Jurkat cells to participate in this stimulation as downstream effectors
of p21ras (9), confirming that this small G protein played a
pivotal role in lymphocyte stimulation. We therefore questioned whether the ERK-2-independent pathway, which is triggered in human primary T
lymphocytes upon X-35 stimulation, involves activation of
p21ras. Fig. 4 shows that
p21ras activation can be detected in UCHT1 (the most intense
band appearing at 5 min) as well as in phorbol ester-treated cells
(used as a control) but not in X-35-stimulated lymphocytes. This
results strongly suggest that X-35 binding to CD3 on purified T cells triggers IL-2 gene transcription through a stimulation pathway independent of p21ras activation.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 4.
p21ras activation in anti-CD3
stimulation. Purified CD4+ T cells were stimulated (5 and 15 min) with X-35 or UCHT1 or with PDBu (5 min) as a control. After
cell lysing, the active form of Ras was pulled down using GST-RDB
fusion protein. After electrophoresis and electroblotting, the membrane
was revealed with anti-Ras mAb. NS, nonstimulated.
|
|
Effect of UCHT1 and X-35 on Early Signals Linked to TCR
Activation--
Upstream of the p21ras/MAP kinase
phosphorylation cascade, the events that are directly induced upon
engagement of the TCR are tyrosine phosphorylation of immunoreceptor
tyrosine-based activation motifs (ITAM) of
and CD3 chains by Src
family tyrosine kinases Fyn and Lck (2). These phosphorylated motifs
provide docking sites for the protein-tyrosine kinases ZAP-70 and Syk,
that are phosphorylated and activated (2, 24). Activation of these protein-tyrosine kinases has been shown to be necessary for propagating downstream signaling. We therefore studied phosphorylation of p56lck, p59fyn, and of ZAP-70 in primary T cells
stimulated either with UCHT1 or X-35; as shown in Fig.
5A, a shifted band can be
observed in p56lck only after a 15-min stimulation with UCHT1
and not with X-35. No activation of p59fyn could be detected
either with UCHT1 or X-35 stimulation (not shown). Concerning ZAP-70,
the presence of which is detected by anti-ZAP-70 Ab, it appears to be
phosphorylated in cells stimulated by both anti-CD3 mAb (Fig.
5B).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 5.
Study of p56lck, ZAP-70, and PKB/Akt
phosphorylation in anti-CD3-stimulated T cells. A,
CD4+ T cells were unstimulated or stimulated (5 and 15 min)
with X-35 or UCHT1. A 5-min stimulation with PdBu was used as a
control. After cell lysis, p56lck was immunoprecipitated.
Activation of p56lck was estimated by its autophosphorylation
in the presence of [ -32P]ATP. This experiment has been
repeated twice. NS, nonstimulated. B, ZAP-70 was
immunoprecipitated from unstimulated cells or from cells previously
treated for 5 min with X-35 or UCHT1. Tyrosine phosphorylation of
ZAP-70 was analyzed using 4G10 anti-phosphotyrosine mAb. This is a
representative experiment of three. C, CD4+ T
cells were unstimulated or stimulated (5 and 15 min) with X-35 or
UCHT1. After cell lysis, total proteins were run on 7.5% SDS-PAGE.
Phosphorylation of PKB/Akt was analyzed using a phosphoserine 473 PKB
antibody. This is a representative experiment of two.
|
|
Recently, it was shown that the two serine/threonine kinases PKB/Akt
(29) and the Tec kinase ITK (30, 31) are phosphorylated and activated
during T cell activation via TCR/CD3. PKB/Akt as well as ITK have a
pleckstrin homology domain (32, 33) that interacts with
membrane-phosphorylated inositol lipids generated by activated
phosphatidylinositol 3-kinase; after recruitment to the cell membrane,
PKB/Akt and ITK are able to be phosphorylated and activated by
PDK1/PDK2 kinases and Src kinases, respectively. PKB/Akt and ITK appear
as downstream targets for phosphatidylinositol 3-kinase (33, 34), the
activity of which has been detected in immunoprecipitates of the
and
chains of the TCR following cell surface engagement of the TCR
(35, 36). We therefore studied activated phosphatidylinositol
3-kinase-dependent phosphorylation of PKB/Akt and ITK. Most
of the studies on ITK activation have been performed using the Jurkat T
cell line. Using highly purified primary T cells we actually failed to
bring evidence of any phosphorylation of ITK immunoprecipitated from
cells activated with one or the other anti-CD3 mAb. In contrast, we
showed (Fig. 5C) that the serine/threonine PKB/Akt, which is
immunoprecipitated in equal quantity from one or the other anti-CD3 mAb
(visualized by a pan-PKB antibody), was phosphorylated only in cells
stimulated with UCHT1 but not in cells activated by X-35 as
revealed by an anti-phospho-PKB antibody. This result suggests that
X-35 does not trigger activation of TCR-related phosphatidylinositol
3-kinase-dependent pathway.
It appears that, except for ZAP-70, which is phosphorylated in both
cases, none of the signals we studied that are commonly described as
activation signals in T cell stimulation via TcR/CD3, are triggered
upon X-35 stimulation. This is in line with what can be observed on
phosphorylation electrophoretic profiles obtained with lysates from
UCHT1- or X-35-stimulated cells (Fig. 6).
Indeed, in UCHT1, several bands appear phosphorylated, whereas in X-35, the profile is very similar to that from unstimulated cells except for
one single band at 58 kDa, which is present in X-35- and not in
UCHT1-activated cells. This 58-kDa band, which we have not yet
characterized, could represent an important signaling intermediate in
the Ras/MEK/ERK-independent pathway triggered by X-35 anti-CD3 mAb.

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 6.
Tyrosine phosphorylation of cellular proteins
upon X-35 and UCHT1 stimulation in CD4+-purified T
cells. CD4+ purified T cells were not stimulated
(NS) or stimulated with anti-CD3 (X-35 and UCHT1, 10 µg/ml) or with PMA (50 ng/ml) for 5 min. After cell lysis, total
proteins were run on 10% SDS-PAGE. Tyrosine-phosphorylated proteins
were analyzed using an anti-phosphotyrosine mAb 4G10. This is a
representative experiment of three.
|
|
 |
DISCUSSION |
The results we present herein provide evidence that activation of
the p21ras/Raf-1/MEK-1/ERK-2 phosphorylation cascade is not an
event obligatorily triggered upon stimulation of purified T lymphocytes
through the TCR/CD3 complex. Moreover they support the related
conclusion that, in primary T cells, IL-2 gene transcription may occur
independently of the activation of the MAP kinase pathway. Indeed we
have shown that, in contrast to the commonly used UCHT1, which triggers
MAP kinase activation, the anti-CD3 mAb X-35 triggers lymphocyte
stimulation leading to IL-2 gene transcription and cell proliferation
without activating ERK-2; moreover, using the MEK-1 inhibitor PD098059, we demonstrated that the blockade of ERK-2 phosphorylation has no
effect on IL-2 mRNA expression induced by X-35. These results demonstrate that the Ras/Raf-1/MEK-1/ERK-2 phosphorylation cascade is
not an exclusive and necessary pathway in TCR/CD3-induced T cell
activation. The possibility of the existence of a MAP
kinase-independent stimulation of T cells has been suggested using
splenocytes from transgenic mice expressing an inactive form of MEK-1
(12); however, as pointed out by others (11), it is unclear whether the
splenic T cells in these transgenic mice, which developed in the
absence of positive selection, are representative of a normal T
lymphocyte population.
It has been demonstrated that Rac-1 participates in the stimulation
process in parallel and in addition to ERK-2 pathway but still as an
effector of p21ras (9); however, a hypothesis of an involvement
of Rac-1 as an effector of Ras seems unlikely since we showed that
p21ras is not activated upon X-35 binding. However, the
possibility remains that in X-35 stimulation, Rac-1 could act instead
of p21ras. Recently Rac-1 and/or CDC-42 were shown to be
involved in NF-AT activation through activation of the serine threonine
kinase Pak-1 (26); however, evidence has been provided that Pak-1 acts
upstream of Ras and participates in a signaling event required for
TCR-mediated Ras activation (26). We analyzed Jun N-terminal kinase
(25) stimulation in both UCHT1 and X-35 activation (data not shown); this kinase appeared very faintly but similarly stimulated in both
cases and, therefore, is probably not involved in this phenomenon.
The difference between the two antibodies in their differential
capacity to stimulate ERK-2 cannot be attributed to the fact that they
are of different isotype; indeed we studied MAP kinase activation using
purified CD4+ T cells totally depleted from Fc
receptor-expressing cells. Moreover, we found that OKT3, an anti-CD3
mAb of the same isotype than X-35, behaves as UCHT1, i.e. it
stimulates ERK-2.
As already described, the two antibodies immunoprecipitate the same
proteins, and their different abilities would therefore be more likely
related to different epitopes recognized by each anti-CD3 mAbs, likely
on the CD3
chain as demonstrated by Tunnacliffe et al.
(15). Recognition of different functional epitopes by the two
antibodies was confirmed in several other studies (37, 38). It is
noteworthy that, on tissue section of human thymus, UCHT1 has been
shown to present a reactivity to medullary and cortical thymocytes,
whereas X-35 reacted only with medullary thymocytes (14).
Our results on proliferative response of purified T cells using
immobilized anti-CD3 or of peripheral blood monocyte cells using
soluble mAb (not shown) bring evidence that the response to X-35 is
higher than that obtained with UCHT1. Such a difference in the response
level between the two antibodies was already observed by others (14). A
higher proliferative response induced by X-35 can be explained by the
fact that higher amounts of IL-2 are produced by X-35 than by UCHT1
(not shown). This higher production of the protein correlates with a
higher expression of IL-2 mRNA in X-35 stimulation. Therefore it
seems that stimulation of the p21ras/ERK-2-independent pathway
triggered by X-35 could be more efficient for IL-2 gene transcription
and IL-2 production. One could then question whether inhibition of the
MAP kinase pathway could be a potentiating factor in activation of
primary T cells. This appears unlikely since we showed that MEK/ERK
inhibition by PD098059 results in the inhibition of IL-2 mRNA
production in UCHT1-stimulated cells. A recent study (39) has also
shown on primary T cells stimulated with a mouse mAb to CD3 (IgE
isotype) that the blockade of the MEK/ERK pathway inhibited IL-2
production but differentially modulated the production of other cytokines.
It appears, however, that the proximal activation induced by both mAbs
after their ligation on CD3 involves phosphorylation of ZAP-70,
suggesting that the respective pathways induced by UCHT1 or X-35
diverge downstream in this protein-tyrosine kinase. Concerning
p56lck or p59fyn, their autophosphorylation is
difficult to detect in primary T cells, and the phosphorylated
p56lck band that appears only in UCHT1-activated cells after a
relatively long time activation (15 min) is probably not due to its
direct autophosphorylation but is likely due to phosphorylation induced by activated ERK-2 as described previously (27, 28). This result is in
line with the fact that UCHT1 triggers ERK-2 activation, whereas X-35
does not.
We also considered two other TCR-related signals, i.e.
activation of the two protein kinases PKB/Akt and ITK; activation of these kinases is dependent on activation of phosphatidylinositol 3-kinase normally triggered following engagement of the TcR/CD3 complex. We failed to detect phosphorylation of ITK in both cases, but
our results show that PKB/Akt is phosphorylated upon UCHT1 treatment
and not upon X-35 stimulation, suggesting that the latter anti-CD3 mAb
does not induce activation of the TCR-related phosphatidylinositol 3-kinase-dependent pathway.
Studying the overall tyrosine phosphorylation of total lysates from
UCHT1- or X-35-stimulated cells, it appears that a single band around
58 kDa is present in X-35 and not in UCHT1 activation. This band
unlikely represents phosphorylated p56lck or p59fyn,
since we showed that phosphorylation of these protein-tyrosine kinases
are difficult to observe in primary T cells even using [
-32P]ATP. However, this band, which is not yet
characterized, could represent an important signaling molecule involved
in the Ras/MEK/ERK-independent pathway triggered by X-35.
Previous studies to explore the role of MAP kinases in TCR function
have looked at regulation of the transcription factor NF-AT in the
Jurkat cell line. In these cells, experiments with inhibitory mutants
of the MAP kinase pathway have suggested that NF-AT activation is
dependent on the Ras/Raf/MEK/ERK signaling cascade. These data now show
that in peripheral blood T cells ERK-2 activation is not an obligatory
signal for IL-2 gene transcription. This illustrates that Jurkat cells,
although a good model for the initial receptor proximal biochemical
processes associated with T cell activation, may not be an appropriate
model for cytokine gene regulation as it relates to primary human T
cells. Interestingly, many of the signaling pathways worked out in
Jurkat cells, particularly in the context of TCR/Ras/MEK/ERK-2
pathways, have been proven to be important as predicted in TCR function
in the thymus.
 |
ACKNOWLEDGEMENTS |
We thank Dr. D. Cantrell (Imperial Cancer
Research Fund, London) for helpful discussion of the results and for
critical reading of the manuscript and Veronica Athié-Morales for
her skillful help in performing Ras experiments.
 |
FOOTNOTES |
*
This work was financially supported by the Fondation Singer
Polignac (France).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of a grant from the federation of European Biochemical Societies.
To whom correspondence should be addressed. Tel.: 33 467 14 42 44; Fax: 33 467 14 33 38; E-mail: favero@univ-montp2.fr.
 |
ABBREVIATIONS |
The abbreviations used are:
IL-2, interleukin-2;
MAP, mitogen-activated protein;
ERK-2, extracellular-regulated
kinase-2;
MEK-1, mitogen-activated ERK kinase;
NF-AT, nuclear factor of
activated T cells;
mAb, monoclonal antibody;
PKB, protein kinase B;
PMA, phorbol 12-myristate 13-acetate;
MBP, myelin basic protein;
GST, glutathione S-transferase;
PDBu, phorbol dibutyrate;
PAGE, polyacrylamide gel electrophoresis;
PVDF, polyvinylidene difluoride;
RDB, Ras binding domain of Raf.
 |
REFERENCES |
| 1.
|
Downward, J.,
Graves, J.,
and Cantrell, D.
(1992)
Immunol. Today
13,
89-92[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Weiss, A.,
and Littman, D. R.
(1994)
Cell
76,
263-274[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Izquierdo-Pastor, M.,
Reif, K.,
and Cantrell, D.
(1995)
Immunol. Today
16,
159-164[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Baldari, C. T.,
Macchia, G.,
and Telford, J. L.
(1992)
J. Biol. Chem.
26,
4289-4291
|
| 5.
|
Rayter, S.,.,
Woodrow, M.,
Lucas, S. C.,
Cantrell, D.,
and Downward, J.
(1992)
EMBO J.
11,
4549-4556[Medline]
[Order article via Infotrieve]
|
| 6.
|
Izquierdo, M.,
Leevers, S. J.,
Marshall, C.,
and Cantrell, D. A.
(1993)
J. Exp. Med.
178,
1199-1208[Abstract/Free Full Text]
|
| 7.
|
Marshall, C. J.
(1994)
Curr. Opin. Genet. Dev.
4,
82-89[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Cobb, M. H.,
and Goldsmith, E. J.
(1995)
J. Biol. Chem.
270,
14843-14846[Free Full Text]
|
| 9.
|
Genot, E.,
Cleverley, S.,
Henning, S.,
and Cantrell, D.
(1996)
EMBO J.
15,
3923-3933[Medline]
[Order article via Infotrieve]
|
| 10.
|
Izquierdo, M.,
Bowden, S.,
and Cantrell, D.
(1994)
J. Exp. Med.
180,
401-406[Abstract/Free Full Text]
|
| 11.
|
Whitehurst, C. E.,
and Geppert, T. D.
(1996)
J. Immunol.
156,
1020-1029[Abstract]
|
| 12.
|
Alberola-Ila, J.,
Forbush, K. A.,
Seger, R.,
Krebs, E. G.,
and Perlmutter, R. M.
(1995)
Nature
373,
620-623[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Bourel, D.,
Genetet, N.,
Merdrignac, G.,
and Genetet, B.
(1987)
Pathol. Biol.
35,
1285-1291[Medline]
[Order article via Infotrieve]
|
| 14.
|
Lobach, D. F.,
Singer, K. H.,
and Haynes, B. F.
(1987)
Leukocyte Typing III
, pp. 174-175, Oxford University Press, Oxford
|
| 15.
|
Tunnacliffe, A.,
Olsson, C.,
and De la Hera, A.
(1989)
Int. Immunol.
1,
546-550[Abstract/Free Full Text]
|
| 16.
|
Lafont, V.,
Rouot, B.,
and Favero, J.
(1998)
Biochem. Pharmacol.
55,
319-324[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Ruckdeschel, K.,
Machold, J.,
Roggenkamp, A.,
Schubert, S.,
Pierre, J.,
Zumbihl, R.,
Liautard, J-P.,
Heesemann, J.,
and Rouot, B.
(1997)
J. Biol. Chem.
272,
15920-15927[Abstract/Free Full Text]
|
| 18.
|
Lafont, V.,
Fischer, T.,
Zumbihl, R.,
Faure, S.,
Hivroz, C.,
Rouot, B.,
and Favero, J.
(1997)
Eur. J. Immunol.
27,
2261-2268[Medline]
[Order article via Infotrieve]
|
| 19.
|
Taylor, S. J.,
and Shalloway, D.
(1996)
Curr. Biol.
6,
1621-1627[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Whitehurst, C. E.,
Boulton, T. G.,
Cobb, M. H.,
and Geppert, T. D.
(1992)
J. Immunol.
148,
3230-3237[Abstract]
|
| 21.
|
Trotta, R.,
Kanakaraj, P.,
and Perussia, B.
(1996)
J. Exp. Med.
184,
1027-1035[Abstract/Free Full Text]
|
| 22.
|
Marais, R.,
Wynne, J.,
and Treisman, R.
(1993)
Cell
73,
381-393[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Dudley, D. T.,
Pang, L.,
Decker, S. J.,
Bridges, A. J.,
and Saltiel, A. R.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7686-7689[Abstract/Free Full Text]
|
| 24.
|
Defranco, A. L.
(1995)
Curr. Opin. Cell Biol.
75,
163-175
|
| 25.
|
Su, B.,
and Karin, M.
(1996)
Curr. Opin. Immunol.
8,
402-411[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Yablonski, D.,
Kane, L. P.,
Qian, D.,
and Weiss, A.
(1998)
EMBO J.
17,
5647-5657[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Watts, J. D.,
Sangherat, J. S.,
Pelech, S. L.,
and Aebersold, R.
(1993)
J. Biol. Chem.
268,
23275-23282[Abstract/Free Full Text]
|
| 28.
|
Gold, M. R.,
Chiu, R.,
Ingham, R. J.,
Saxton, T. M.,
Van Ooosten, I.,
Watts, J. D.,
Affolter, M.,
and Aebersold, R.
(1994)
J. Immunol.
153,
2369-2380[Abstract]
|
| 29.
|
Genot, E.,
Reif, K.,
Beach, S.,
Kramer, I.,
and Cantrell, D.
(1998)
Oncogene.
17,
1731-1738[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Gibson, S.,
August, A.,
Kawakami, Y.,
Kawakami, T.,
Dupont, B.,
and Mills, G. B.
(1996)
J. Immunol.
156,
2716-2722[Abstract]
|
| 31.
|
Yang, W. C.,
Ghiotto, M.,
Barbarat, B.,
and Olive, D.
(1999)
J. Biol. Chem.
274,
607-617[Abstract/Free Full Text]
|
| 32.
|
Frech, M.,
Andjelkovic, M.,
Ingley, E.,
Reddy, K. K.,
Falck, J. R.,
and Hemmings, B. A.
(1997)
J Biol Chem.
272,
8474-8481[Abstract/Free Full Text]
|
| 33.
|
August, A.,
Sadra, A.,
Dupont, B.,
and Hanafusa, H.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11227-11232[Abstract/Free Full Text]
|
| 34.
|
Boudewijn, M.,
Burgering, T. H.,
and Coffer, P. J.
(1995)
Nature
376,
599-602[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Exley, M.,
Varticovski, L.,
Peter, M.,
Sancho, J.,
and Terhorst, C.
(1994)
J. Biol. Chem.
269,
15140-15146[Abstract/Free Full Text]
|
| 36.
|
de Aos, I.,
Metzger, M. H.,
Exley, M.,
Dahl, C. E.,
Misra, S.,
Zheng, D.,
Varticovski, L.,
Terhorst, C.,
and Sancho, J.
(1997)
J. Biol. Chem.
272,
25310-25318[Abstract/Free Full Text]
|
| 37.
|
Yang, S. Y.,
Rhee, S.,
Angelos, G.,
and Dupont, B.
(1987)
Leukocyte Typing III
, pp. 116-119, Oxford University Press, Oxford
|
| 38.
|
Denning, M. D.,
Tuck, D. T.,
Singer, K. H.,
and Haynes, B. F.
(1987)
Leukocyte Typing III
, pp. 144-147, Oxford University Press, Oxford
|
| 39.
|
Dumont, F. J.,
Staruch, M. J.,
Fisher, P.,
DaSilva, C.,
and Camacho, R.
(1998)
J. Immunol.
160,
2579-2589[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Scotta, M. Soligo, C. Camperio, and E. Piccolella
FOXP3 Induced by CD28/B7 Interaction Regulates CD25 and Anergic Phenotype in Human CD4+CD25- T Lymphocytes
J. Immunol.,
July 15, 2008;
181(2):
1025 - 1033.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Jimenez de Bagues, A. Gross, A. Terraza, and J. Dornand
Regulation of the Mitogen-Activated Protein Kinases by Brucella spp. Expressing a Smooth and Rough Phenotype: Relationship to Pathogen Invasiveness
Infect. Immun.,
May 1, 2005;
73(5):
3178 - 3183.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Bostik, A. E. Mayne, F. Villinger, K. P. Greenberg, J. D. Powell, and A. A. Ansari
Relative Resistance in the Development of T Cell Anergy in CD4+ T Cells from Simian Immunodeficiency Virus Disease-Resistant Sooty Mangabeys
J. Immunol.,
January 1, 2001;
166(1):
506 - 516.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.